Core Viewpoint - The company has repurchased a total of 7.627 million shares under its share buyback authorization from October 21, 2025, to December 17, 2025, indicating confidence in its long-term growth and market performance [1] Group 1 - The board believes the current stock price is below its true value and does not reflect the company's business prospects adequately [1] - The share buyback plan has been extended until the conclusion of the next annual general meeting, demonstrating the board's commitment to shareholder interests [1] - The board has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 335,000 shares between November 6, 2025, and December 17, 2025, increasing their total holdings to 218,283,730 shares, representing approximately 38.2% of the total issued shares [1] Group 2 - The board views the increase in shareholding by major shareholders as a sign of confidence in the company's future and growth potential, as well as recognition of its long-term investment value [1]
科济药业-B累计回购762.7万股 益杰一致行动集团增持33.5万股